Improved assay of cardiac troponin I is more sensitive than other assays of necrosis markers

Abstract

Objective. Highly sensitive and specific assays of cardiac troponins I and T are the preferred biomarkers in diagnosing myocardial infarction (MI). Assays of cardiac troponin I (cTnI) have been improved with the addition of antibodies against the cTnI molecule and may have increased sensitivity. We hypothesized that a cTnI assay with modern antibody configuration will exhibit equal or better sensitivity in the setting of acute MI compared to cTnT and other markers of myocardial necrosis. Material and methods. We investigated release kinetics of cTnI (Abbott ADV, Abbott Diagnostics), cTnT (Roche Diagnostics), CKMBmass, myoglobin and heart fatty acid binding protein (H‐FABP) in 23 patients admitted with acute ST‐segment elevation MI undergoing primary percutaneous coronary intervention. Calibrators for the Abbott ADV cTnI assay are traceable to the United States National Institute of Standards and Technology (NIST) reference material for cTnI. Eleven blood samples were drawn from each patient in the period from admission to 24 h. Biomarkers of necrosis showed marked increases in relative concentrations, especially within the first 2 h after admission. Results. From 30 min after admission onwards, cTnI exhibited significantly higher relative concentrations compared to cTnT, CKMBmass, Myoglobin and H‐FABP (p<0.05). Conclusions. The NIST standardized Abbott TnI ADV assay appears to be more sensitive than cTnT and other biomarkers in the early phase of MI.

• Troponin
• troponin I
• troponin T
• myocardial infarction
• myocardial disease
• Myoglobin, creatine Kinase MB form
• heart‐type fatty acid‐binding protein, human
• sensitivity and specificity

Acknowledgements

We thank the staff at the Clinical Chemistry Units at Aalborg and Bispebjerg Hospitals for providing excellent technical assistance in analysing blood samples. We are also grateful to Roche Diagnostics, Denmark and Abbott Diagnostics, Denmark for providing assays.